PANTS extension study: how best to use anti-TNF drugs in Crohn's disease

Although the past 10 years have brought a wave of novel medications and mechanisms to the management of Crohn's disease and inflammatory bowel disease (IBD), anti-TNF therapy remains a cornerstone of treatment, and due to the development of biosimilar agents, remains highly cost effective. The recently published PROFILE trial has highlighted that impressively high 1-year remission rates can be obtained when anti-TNF therapies are introduced very early in disease management.1 However, a drawback of adopting earlier introduction of biologics is a drive towards increased use of advanced therapies in Crohn's disease, with an impact on cost for payers.